CSL LIMITED (CSL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CSL - CSL LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Index: ASX20 | ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

CSL is a global biotechnology company that researches, develops, manufactures and markets products for the treatment of human diseases. With a market cap of over $138bn it is one of Australia's top three largest index weights. The former Commonwealth Serum Laboratory listed in June 1994 and has generated an average annual return of 28% since (up until mid-2020). CSL is the world's largest collector of plasma and the second largest producer of vaccines.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$277.25

16 May
2022

-2.950

OPEN

$279.87

-1.05%

HIGH

$279.99

550,739

LOW

$276.27

TARGET
$319.02 15.1% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
CUV . ACR . AHZ . IDT . IVX . MSB . MYX . RNO . OSL . TFC . TIS . KZA . AGH . FTT . PAR . ADO . PYC . RAC . RCE . ZNO . AVH . LGP . SPL . ARX . AFP . 1AD . TLX . PNV . MVP . BNO . NXS . GSS . EOF . NEU . PAL . PBP . BOT . IMU . MDC . IMM . PXS . HXL . MXC . OPT . ANP .
FNARENA'S MARKET CONSENSUS FORECASTS
CSL: 1
Title FY22
Forecast		 FY23
Forecast
EPS (cps) 670.3 xxx
DPS (cps) 289.4 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 40.9 xxx
Dividend Yield 1.1% xxx
Div Pay Ratio(%) 43.2% xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 1.53%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.15

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 07/03 - ex-div 145.92c (franking 0%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2022 FactSet UK Limited. All rights reserved
Title 201620172018201920202021
EPS Basic xxxxxxxxxxxxxxx700.0
DPS All xxxxxxxxxxxxxxx293.9
Sales/Revenue xxxxxxxxxxxxxxx13,761.5 M
Book Value Per Share xxxxxxxxxxxxxxx2,452.9
Net Operating Cash Flow xxxxxxxxxxxxxxx4,855.5 M
Net Profit Margin xxxxxxxxxxxxxxx23.14 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201620172018201920202021
Return on Capital Employed xxxxxxxxxxxxxxx30.84 %
Return on Invested Capital xxxxxxxxxxxxxxx17.61 %
Return on Assets xxxxxxxxxxxxxxx13.65 %
Return on Equity xxxxxxxxxxxxxxx30.84 %
Return on Total Capital xxxxxxxxxxxxxxx22.31 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx1,967.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.9

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

12/04/2022

1

Outperform

$327.50

18.12%

Taking a closer look at Vifor Pharma as CSL's acquisition progresses, Macquarie notes the company has a strong market position in iron deficiency and chronic kidney disease and offers an attractive earnings growth profile through to FY24.

The company's Ferinject/Injectafer product has shown strong growth in the last decade, delivering a 31% compound annual growth rate since 2012, and looking ahead Macquarie notes areas for expansion and new product development. 

The Outperform rating and target price of $327.50 are retained.

FORECAST
Macquarie forecasts a full year FY22 dividend of 246.66 cents and EPS of 664.35 cents.
Macquarie forecasts a full year FY23 dividend of 357.05 cents and EPS of 819.02 cents.

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Credit Suisse

xx/xx/xxxx

-1

xx xxxxxx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

CSL STOCK CHART

FNArena News on CSL

1
Rudy’s View: Trend Is Turning For Corporate Profits

May 12 2022 - Rudi's View
2
Rudi’s View: Ampol, CSL, Temple & Webster And WiseTech Global

Apr 28 2022 - Rudi's View
3
CSL: Buy Trigger Ahead

Apr 26 2022 - Technicals
4
Rudi’s View: Peter’s Portfolio Reviewed

Apr 13 2022 - Rudi's View
5
Rudi’s View: Real Market Support Is Invisible

Apr 07 2022 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL: Buy Trigger Ahead

Apr 26 2022 - Technicals
2
Why CSL Fell Sharply Yesterday

Dec 17 2021 - Australia
3
Beating The Biotech Blues

Sep 14 2021 - International
4
Uncertainty Prevails For CSL

Aug 19 2021 - Australia
5
Flying High – Medicinal Marijuana In Australia

Jul 26 2021 - Australia
6
Wesfarmers On Drugs?

Jul 13 2021 - Australia
7
Is CSL’s Plasma Recovery Now Priced In?

Jun 23 2021 - Australia
8
CSL: Buy The Dip

Jun 22 2021 - Technicals
9
CSL To Retest Its High?

May 25 2021 - Technicals
10
Treasure Chest: CSL Plasma At Turning Point?

May 05 2021 - Treasure Chest